Shares of Eli Lilly came under selling pressure following an announcement by the U.S. Food and Drug Administration (FDA) regarding a delay for one of its anticipated new products. The regulatory body has postponed its decision on orforglipron, the company’s novel oral weight-loss medication, pushing the target action date to April 10, 2026. This represents a significant shift from the prior expectation of a first-quarter 2025 approval.
Market Reaction and Short-Term Implications
The immediate market response reflected investor disappointment over the postponed launch timeline for a drug with substantial commercial potential. Regulatory delays inherently create uncertainty, and this shift is expected to defer revenue generation from this asset. The news triggered profit-taking from investors who had been positioning for the next major product in the lucrative GLP-1 therapy market, which addresses obesity and diabetes.
Despite this near-term setback, the company’s broader strategic position remains robust. Eli Lilly continues to dominate the GLP-1 sector with its currently marketed therapies and maintains a strong pipeline of other developmental drugs.
Sustained Analyst Confidence and Financial Health
Leading financial institutions have largely maintained their positive outlook on Eli Lilly’s stock, with several reiterating or raising their price targets in recent assessments. Analysts at Jefferies Financial Group increased their target to $1,300. Similarly, UBS maintains a $1,250 target, and Bank of America forecasts $1,268. The consensus price target among analysts stands at approximately $1,174, indicating a considerable upside from the recent trading level around $1,038.
Should investors sell immediately? Or is it worth buying Eli Lilly?
This enduring confidence is underpinned by exceptionally strong fundamental performance. The pharmaceutical giant reported a year-over-year revenue surge of 53.9% in its most recent quarter. For the twelve-month period ending September 2025, total revenue reached $59.42 billion. The company has demonstrated a three-year average sales growth of 23.4%. Furthermore, Eli Lilly has declared a quarterly dividend of $1.73 per share for the first quarter of 2026.
Strategic Diversification: A Major AI Partnership
Alongside its core pharmaceutical operations, Eli Lilly is making a strategic push into advanced technology. In a notable cross-industry move, the company has partnered with chipmaker Nvidia to establish a $1 billion artificial intelligence (AI)-driven research facility. This collaboration is specifically designed to accelerate the drug discovery process and enhance productivity in pharmaceutical development by leveraging cutting-edge computational power.
Looking Ahead
The investment community’s focus now turns to the revised FDA decision date in April 2026 for orforglipron, as well as the continued expansion of Eli Lilly’s overall GLP-1 portfolio. The company’s underlying operational growth remains vigorous, and its development pipeline continues to be viewed as highly promising by industry observers.
Ad
Eli Lilly Stock: Buy or Sell?! New Eli Lilly Analysis from January 19 delivers the answer:
The latest Eli Lilly figures speak for themselves: Urgent action needed for Eli Lilly investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from January 19.
Eli Lilly: Buy or sell? Read more here...
